Related Experiment Videos
[Lichenoid cutaneous reaction to imatinib]
C Roux1, A-M Boisseau-Garsaud, I Saint-Cyr
1Service de Dermatologie et Vénéréologie, CHU La Meynard, Hôpital Pierre Zobda Quitman, Fort-de-France, Martinique.
Annales De Dermatologie Et De Venereologie
|August 20, 2004
Summary
This case study highlights a rare, profuse lichenoid drug eruption in a chronic myeloid leukemia patient treated with imatinib. The eruption resolved upon drug cessation and recurred upon reintroduction, confirming imatinib
Area of Science:
- Dermatology
- Oncology
- Pharmacology
Background:
- Imatinib (Glivec) is a targeted therapy for chronic myeloid leukemia (CML).
- While cutaneous side effects are common with imatinib, lichenoid drug eruptions are rare.
Observation:
- A 52-year-old female CML patient developed a disseminated, pruritic, dark purple papular eruption.
- The eruption, appearing two months after initiating imatinib (400 mg/day), was histologically confirmed as lichen planus.
- Lesions affected the trunk, legs, arms, and face, with no mucosal involvement.
Findings:
- Discontinuation of imatinib led to complete resolution of the cutaneous eruption within two months.
- Re-administration of imatinib resulted in the recurrence of the lichenoid lesions.
- Imputability analysis strongly suggests imatinib as the causative agent for the lichenoid drug eruption.
Implications:
- This case represents the first reported instance of a profuse cutaneous lichenoid eruption linked to imatinib therapy.
- Clinicians should consider imatinib-induced lichenoid drug eruption in CML patients presenting with similar dermatological symptoms.
- The findings underscore the importance of monitoring for rare but significant cutaneous adverse events during imatinib treatment.